- Visibility 49 Views
- Downloads 46 Downloads
- Permissions
- DOI 10.18231/j.ijced.22304.1758868077
-
CrossMark
Decoding dermatologic dilemmas: Assessment of cutaneous adverse drug reactions at a tertiary care hospital in South India - A retrospective study
- Author Details:
-
Nafeesath Jafna
-
Dhivya Palaniappan *
-
Seethalakshmi Ganga Vellaisamy
-
Navakumar Manickam
-
Kannan Gopalan
Dhivya Palaniappan *
Background: The incidence of adverse cutaneous drug reaction (cADR) varies from 2-3% among hospitalized patients. Around 2% of all cADR may be severe and end in fatalities.
cADR can range from mild, exanthematous rash to severe, life-threatening reactions.
Objective: This study aimed to draw association between potential offensive drugs and the ensuing cutaneous adverse reactions, and to assess the various morphological patterns and severity of reported adverse reactions.
Materials and Methods: This was an observational study conducted between February 2023 and March 2024 in a tertiary care hospital in Tamil Nadu. A total of 63 patients with cADR were evaluated for a period of one year. Detailed history, clinical examination and relevant investigations, along with treatment outcomes were analysed.
Results: We noted a wide spectrum of cADR ranging from maculopapular eruption and fixed drug eruption to severe cutaneous adverse reactions (SCARs) like SJS/TEN. Antimicrobials were identified as the major factor associated, followed by NSAIDs. The most common presentation of cADR was fixed drug eruption (46%) followed by maculopapular eruption (17.5%). SCARs accounted for 26.9% of the total cADR in our study. SJS/TEN overlap (12.7%) was the most common SCAR we observed in our study, the most frequent drugs implicated in SCAR were antiepileptics (25%).
Conclusion: The most common cADR observed in this study was FDE and antibiotics were the most commonly associated agents.
References
- Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol. 2012;78(6):734–9.
- Valeyrie-Allanore L, Obeid G, Revuz J. Drug Reactions. In: Bolognia JL. Dermatology, 4th ed. China: Elsevier; 2018:348.
- Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra 2002;2:1-16.
- Grover S. Severe cutaneous adverse reactions. Indian J Dermatol Venereol Leprol. 2011;77(1):3–6
- Aboud D, Nessel T, Hafsi W. Cutaneous Adverse Drug Reaction. Treasure Island (FL): StatPearls Publishing; 2024.
- Niebel D, Wenzel J. [Immunopathology of cutaneous drug eruptions]. Pathologe. 2018;39(6):563–70.
- Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53(1):2–8.
- A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
- Amrinder R, Kaur I, Singh J, Kaur T. Monitoring of Cutaneous Adverse Drug Reactions in a Tertiary Care Hospital. J Pharmacovigilance. 2016;4(3):1-4.
- Lakshmi R, Anoop T, Rajiv S, Ajayakumar S, Sparshadeep EM, Divakaran B. A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in South India. Clin Dermatol Rev. 2021;5(2):173–7.
- Pudukadan D, Thappa DV. Adverse cutaneous drug reactions: Clinical pattern and causative agents in a tertiary care center in South India. Indian J Dermatol Venereol Leprol. 2004;70(1):20-4.
- Chatterjee S, Ghosh AP, Barbhuiya J, Dey SK. Adverse cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol. 2006;38(6):429–31.
- Sharma, VK, Sethuraman G, Kumar B. Cutaneous Adverse Drug Reactions: Clinical Pattern and Causative Agents — A 6 Year Series From Chandigarh, India. J Postgrad Med. 2001;47(2):95–9.
- Borch JE, Andersen KE, Bindslev-Jensen C. Prevalence of acute cutaneous drug reactions in a University hospital. Acta Derm Venereol. 2006;86(6):518–22.
- .Jha N, Alexander E, Kanish B, Badyal DK. A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab. Indian Dermatol Online J. 2018;9(5):299–303.
- Nandha R, Gupta A, Hashmi A. Cutaneous adverse drug reactions in a tertiary care teaching hospital: A North Indian perspective. Int J Appl Basic Med Res. 2011;1(1):50–3.
- Hafner JW, Belknap SW, Squillante MD, Bucheit KA. Adverse drug events in emergency department patients. Ann Emerg Med. 2002;39(3):258–67.
- Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systemic review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389–98. Jafna et al. / IP Indian Journal of Clinical and Experimental Dermatology 2025;11(3):320-327 327
- Roujeau JC, Allanore L, Liss Y, Mockenhaupt M. Severe Cutaneous Adverse Reactions to Drugs (SCAR): Definitions, Diagnostic Criteria, Genetic Predisposition. Dermatol Sinica. 2009;27:203–9. Annexure Question Yes No Do Not Know Score
- Are there previous conclusive reports on this reaction? +1 0 0
- Did the adverse event appear after the suspected drug was administered? +2 -1 0
- Did the adverse event improve when the drug was discontinued or a specific antagonist was administered? +1 0 0
- Did the adverse event reappear when the drug was readministered? +2 -1 0
- Are there alternative causes that could on their own have caused the reaction? -1 +2 0
- Did the reaction reappear when a placebo was given? -1 +1 0
- Was the drug detected in blood or other fluids in concentrations known to be toxic? +1 0 0
- Was the reaction more severe when the dose was increased or less severe when the dose was decreased? +1 0 0
- Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0
- Was the adverse event confirmed by any objective evidence? +1 0 0 Total Score: